These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 8746883)
1. Prevention of post-oophorectomy bone loss with Tibolone. Lyritis GP; Karpathios S; Basdekis K; Grigoriou O; Katostaras T; Paspati I; Stamatopoulos T; Siampalioti G; Lyritis PG Maturitas; 1995 Nov; 22(3):247-53. PubMed ID: 8746883 [TBL] [Abstract][Full Text] [Related]
2. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone. Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492 [TBL] [Abstract][Full Text] [Related]
3. Effects of 8 years of treatment with tibolone 2.5 mg daily on postmenopausal bone loss. Rymer J; Robinson J; Fogelman I Osteoporos Int; 2001; 12(6):478-83. PubMed ID: 11446564 [TBL] [Abstract][Full Text] [Related]
4. A longitudinal evaluation of the effect of two doses of tibolone on bone density and metabolism in early postmenopausal women. Gambacciani M; Ciaponi M; Cappagli B; Monteleone P; Benussi C; Bevilacqua G; Genazzani AR Gynecol Endocrinol; 2004 Jan; 18(1):9-16. PubMed ID: 15106359 [TBL] [Abstract][Full Text] [Related]
5. Effects of tibolone (Org OD14) treatment for 3 months on ovariectomy-induced osteopenia in 8-month-old rats on a low-calcium diet: preventive testing for 3 months. Kasugai Y; Ikegami A; Matsuo K; Ohashi M; Sukamoto T; Hosoi T; Ouchi Y; Orimo H Bone; 1998 Feb; 22(2):119-24. PubMed ID: 9477234 [TBL] [Abstract][Full Text] [Related]
6. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone. Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347 [TBL] [Abstract][Full Text] [Related]
7. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Berning B; Kuijk CV; Kuiper JW; Bennink HJ; Kicovic PM; Fauser BC Bone; 1996 Oct; 19(4):395-9. PubMed ID: 8894146 [TBL] [Abstract][Full Text] [Related]
8. Increased loss of trabecular but not cortical bone density, 1 year after discontinuation of 2 years hormone replacement therapy with Tibolone. Berning B; van Kuijk C; Kuiper JW; Coelingh Bennink HJ; Fauser BC Maturitas; 1999 Jan; 31(2):151-9. PubMed ID: 10227009 [TBL] [Abstract][Full Text] [Related]
9. Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Rymer J; Robinson J; Fogelman I Climacteric; 2002 Dec; 5(4):390-8. PubMed ID: 12626219 [TBL] [Abstract][Full Text] [Related]
10. Tibolone: prevention of bone loss in late postmenopausal women. Bjarnason NH; Bjarnason K; Haarbo J; Rosenquist C; Christiansen C J Clin Endocrinol Metab; 1996 Jul; 81(7):2419-22. PubMed ID: 8675554 [TBL] [Abstract][Full Text] [Related]
11. Prevention of postmenopausal bone loss at lumbar spine and upper femur with tibolone: a two-year randomised controlled trial. Beardsworth SA; Kearney CE; Purdie DW Br J Obstet Gynaecol; 1999 Jul; 106(7):678-83. PubMed ID: 10428524 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. Yang TS; Tsan SH; Chen CR; Chang SP; Yuan CC Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):308-15. PubMed ID: 10389286 [TBL] [Abstract][Full Text] [Related]
13. Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats. Ederveen AG; Kloosterboer HJ J Bone Miner Res; 1999 Nov; 14(11):1963-70. PubMed ID: 10571697 [TBL] [Abstract][Full Text] [Related]
14. Comparison of combined low-dose hormone therapy vs. tibolone in the prevention of bone loss. Kalder M; Kyvernitakis I; Hars O; Kauka A; Hadji P Climacteric; 2016 Oct; 19(5):471-7. PubMed ID: 27345158 [TBL] [Abstract][Full Text] [Related]
15. Tibolone and its effects on bone: a review. Berning B; Bennink HJ; Fauser BC Climacteric; 2001 Jun; 4(2):120-36. PubMed ID: 11428176 [TBL] [Abstract][Full Text] [Related]
17. Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17 beta-estradiol for hormonal replacement therapy in women with surgical menopause. Mendoza N; Suárez AM; Alamo F; Bartual E; Vergara F; Herruzo A Maturitas; 2000 Nov; 37(1):37-43. PubMed ID: 11099872 [TBL] [Abstract][Full Text] [Related]
18. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. Gallagher JC; Baylink DJ; Freeman R; McClung M J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531 [TBL] [Abstract][Full Text] [Related]
19. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Studd J; Arnala I; Kicovic PM; Zamblera D; Kröger H; Holland N Obstet Gynecol; 1998 Oct; 92(4 Pt 1):574-9. PubMed ID: 9764631 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Pavlov PW; Ginsburg J; Kicovic PM; van der Schaaf DB; Prelevic G; Bennink HJ Gynecol Endocrinol; 1999 Aug; 13(4):230-7. PubMed ID: 10533157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]